PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance

Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 -$75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif., April 16, 2024 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results Preliminary revenue of $38.8 million, roughly flat compared with$38.9 million in the prior-year period. Instrument revenue of $19.0 million compared with$20.7 million in the pr ...